AVROBIO announces merger with Tectonic Therapeutic in significant all-stock deal

AVROBIO announces merger with Tectonic Therapeutic in significant all-stock deal

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc., a biotechnology firm specializing in GPCR (G-protein coupled receptor)-targeted therapeutic proteins, have announced a definitive merger agreement. This all-stock transaction will result in AVROBIO acquiring 100% of Tectonic’s outstanding equity interests, with the merged entity operating under the name Tectonic Therapeutic, Inc. and trading on Nasdaq under […]

Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease

Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease

US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment of Gaucher disease, from the US Food and Drug Administration (FDA). AVR-RD-02 is made up of the patient’s own hematopoietic stem cells, which are modified genetically to express glucocerebrosidase (GCase), an enzyme that is deficient in Gaucher […]